MedTrace Logo

A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection

NCT07694557 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-07-10

No results posted yet for this study

Summary

A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection

Conditions

  • Respiratory Syncytial Virus (RSV)

Interventions

DRUG

YKYY025 group

intramuscular, a single intramuscular injection of the corresponding dose of YKYY025 for injection

DRUG

YKYY025 Placebo group

intramuscular, a single intramuscular injection of the corresponding dose of YKYY025 Placebo

Sponsors & Collaborators

  • Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-15
Primary Completion
2028-07-01
Completion
2028-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07694557 on ClinicalTrials.gov